Briceño ED, Naranjo-Gomez AL

Idioma: Español
Referencias bibliográficas: 26
Paginas: 19-27
Archivo PDF: 650.68 Kb.

RESUMEN

El glioblastoma recurrente es un problema frecuente al que se enfrentan neurólogos, neurooncólogos, neuroradiólogos y neurocirujanos debido a la mala respuesta a los esquemas de terapia. Se presenta una serie de casos de 15 pacientes diagnosticados con glioblastoma recurrente sin opción a intervención quirúrgica y/o radioterapia, de entre 18 y 75 años (con una media de 55 años), tratados con terapia combinada bevacizumab y ciclofosfamida después con refractariedad a otros esquemas de quimioterapia, durante éste seguimiento se observó un tiempo libre de progresión entre 6 a 21 meses, media de 9 meses y supervivencia de 9.3 meses con un bajo grado de toxicidad durante el seguimiento considerando este esquema, como una opción terapéutica alternativa.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Sorensen AG, Emblem KE, Polaskova P, Jennings D,Kim H, Ancukiewicz M, Wang M, Wen PY, Ivy P,Batchelor TT, Jain RK: Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res 2012; 72:402–7.

2. Roos WP, Batista LF, Naumann SC, Wick W, Weller M, Menck CF, Kaina B. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6- methylguanine. Oncogene 2007; 26:186–197.

3. Cahill DP, Levine KK, Betensky RA, Codd PJ, Romany CA, Reavie LB, Batchelor TT, Futreal PA, Stratton MR, Curry WT, Iafrate AJ, Louis DN. Loss of the mismatch repair protein MSH_6_ in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res 2007;13:2038–45.

4. Marc C Chamberlain. Role for cytotoxic chemotherapy in patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series, Expert Rev. Neurother 2012; 12(8): 929–36.

5. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JG. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000; 343:1350–4.

6. Liu L, Gerson SL. Targeted modulation of MGMT: clinical implications. Clin Cancer Res 2006; 12: 328–31.

7. Shchors K, Persson AI, Rostker F, Tihan T, Lyubynska N, Li N, Swigart LB, Berger MS, Hanahan D, Weiss WA, Evan GI. Using a preclinical mouse model of high-grade astrocytoma to optimize p53 restoration therapy. Proc Natl Acad Sci USA 2013; 110:E1480–1489.

8. Mizoguchi M, Guan Y, Yoshimoto K, Hata N, Amano T, Nakamizo A, Sasaki T. Clinical implications of microRNAs in human glioblastoma. Front Oncol 2013; 3:19.

9. Llopis-García. Modelado farmacocinético de ciclofosfamida en pacientes con cáncer de mama.2019 http://roderic. uv.es/handle/10550/23297

10. Marc C, Chamberlain. Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme.2004 American Cancer Society. https://doi.org/10.1002/cncr.20072

11. Jakobsen, Urup K, Grunnet A. Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients Journal of Neuro-Oncology 2018; 37 (2): 439–446. https://link.springer.com/article/10.1007%2Fs11060-017-2736-x

12. Gramatzki D, Roth P, Rushing EJ, et. al. Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study. Annals of Oncology 2018; 29(6):1431–36. https://doi.org/10.1093/annonc/ mdy106

13. Yoshiki Arakawa, et. al. Retrospective Analysis of bevacizumab in combination with ifosfamide, carboplatin, and etoposide in patients with second recurrence of glioblastoma. Neurol Med Chir (Tokyo) 2013; 53: 779–85.

14. Burger, Breuer S, Cieplik H, et. al. Bevacizumab for patients with recurrent multifocal glioblastomas. Int J Mol Sci 2017; 18, 2469. doi:10.3390/ijms18112469

15. Franceschi E, Lamberti G, Paccapelo A, Genestreti G, Minichillo S, et. al. Third-line therapy in recurrent glioblastoma: is it another chance for bevacizumab?. J Neuro-Oncology 2018; 139(2): 383–88.

16. Yamamoto Y, Tamura R, et. al. Paradoxical ”findings of tumor vascularity and oxygenation in recurrent glioblastomas refractory to bevacizumab. Oncotarget 2017; 8(61). DOI: 10.18632/oncotarget.21978

17. Guías distinguidas, serie farmacología vol1 abril 2014 criterios de terminología de eventos adversos Institute National Cancer de los Estados Unidos (NCI)

18. NCCN guidelines. Central Nervous System Cancers Version 1.2017

19. Seung Ho Yang, Shenglan Li, Guangrong Lu, Ying Liu. Metformin treatment reduces temozolomide resistance of glioblastoma cells. Oncotarget 2016; 7(48).

20. Stuup R, Mason WP, van den Bent MJ ,Weller M, et.al. Radiotherapy plus concomitante and adjuvant temozolomide for glioblastoma Nengl J med 2005; 352: 987-96.

21. Friedman HS, Prados MD, Wen PY, et. al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27(28): 4733–40.

22. Kreisl TN, Kim L, Moore K, et. al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009;27(5):740–45.

23. Browder T, Butterfield CE, Kraling BM, et. al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drugresistant cancer. Cancer Res 2000; 60:1878–86.

24. Miller KD, Sweeney CJ, Sledge GW Jr. Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 2001;19:1195–1206.

25. Asou N, Suzushima H, Nishimura S, et. al. Long-term remission in an elderly patient with mantle cell leukemia treated with low-dose cyclophosphamide. Am J Hematol 2000;63:35–37.

26. Kesari S, Schiff D, Doherty L, Gigas DC, Batchelor TT, Muzikansky A, O’Neill A, et. al. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neuro-Oncol 2007; 9(3): 354-363.